phosphatidylinositol glycan anchor biosynthesis class A
Zuletzt aktualisiert 24 Feb 2022
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
The PIGA gene provides instructions for making a protein called phosphatidylinositol glycan class A (shortened to PIG-A). The PIG-A protein takes part in a series of steps that produce a molecule called glycophosphatidylinositol (GPI) anchor. Specifically, the PIG-A protein is one piece of a group of proteins (a complex) that performs the first step of the series, which produces an intermediate molecule called N-acetylglucosaminyl phosphatidylinositol, or GlcNAc-PI.
Normal function
The PIGA gene provides instructions for making a protein called phosphatidylinositol glycan class A (shortened to PIG-A). The PIG-A protein takes part in a series of steps that produce a molecule called glycophosphatidylinositol (GPI) anchor. Specifically, the PIG-A protein is one piece of a group of proteins (a complex) that performs the first step of the series, which produces an intermediate molecule called N-acetylglucosaminyl phosphatidylinositol, or GlcNAc-PI.
The GPI anchor, the ultimate product of the series of steps, attaches many different proteins to the cell membrane. These proteins are known as GPI-anchored proteins. Anchored proteins have a variety of roles, including sticking cells to one another, relaying signals into cells, and protecting cells from destruction.
Conditions referring to this gene or chromosome
Other names
GLCNAC-PI synthesis protein
GPI anchor biosynthesis
GPI3
phosphatidylinositol glycan anchor biosynthesis, class A
phosphatidylinositol glycan anchor biosynthesis, class A (paroxysmal nocturnal hemoglobinuria)
phosphatidylinositol glycan, class A (paroxysmal nocturnal hemoglobinuria)
phosphatidylinositol N-acetylglucosaminyltransferase subunit A
phosphatidylinositol-glycan biosynthesis, class A protein
PIG-A
PIGA_HUMAN
Related patient information and medicines
Patient information leaflet
Freizeitdrogen
These are published regularly. The latest statistics at the time of writing this leaflet are from the year ending March 2024: An estimated 8.8% of adults aged 16-59 had taken a drug in the last year (2.9 million people). This rises to 16.5% amongst 16-24 year olds. 1.8% of adults aged 16-59 use drugs frequently (more than once a month). 3% of.
Patient information leaflet
Mitralklappenstenose
Mitralklappenstenose means that when the mitral valve opens, it does not open fully. The opening is therefore narrower than normal (stenosed). The mitral valve ist a heart valve that lies between the left atrium and left ventricle. The valve has two flaps (cusps). The valve allows blood to flow into the left ventricle when the left atrium squeezes.
Patient information leaflet
Medikamente und Behandlung bei Demenz
Medicines for dementia sind used to help with symptoms that affect thinking and memory, as well as symptoms that affect mood and behaviour. But there are also many non-drug treatments that can help support a person with dementia. Dementia medication Medicines for dementia are used firstly as a treatment to help with symptoms that affect thinking.
Patient information leaflet
Blutgruppen und -typen
ABO und rhesus are both types of antigens found on the surface of red blood cells. There are lots of other types but these are the most important. The main reasons to know your blood group are if you need to have a blood transfusion or if you are pregnant. What is a blood group. Red blood cells (erythrocytes) have certain proteins on their.
Patient information leaflet
Cushing-Syndrom
Cushing's syndrome is caused by too high a level of glucocorticoid in the body. This can be caused by taking steroid medication long-term (the common cause) or by the body making too much cortisol (the main glucocorticoid made by the body). There are various reasons why the body may produce too much cortisol, and complex tests may be needed to.
Patient information leaflet
Ärztliche Fahrlässigkeit
Es gibt a separate Health Service Ombudsman for England, Scotland, Wales und Northern Ireland. Governing bodies for health prof... The Gesundheit und Care Professions Council (HCPC), for art therapists, biomedical scientists, chiropodists and podiatrists, clinical scientists, dieticians, hearing aid dispensers, occupational therapists, operating.
Weiterführende Lektüre und Referenzen
- phosphatidylinositol glycan anchor biosynthesis class A; MedlinePlus, National Library of Medicine.
- Brodsky RA, Hu R. PIG-A mutations in paroxysmal nocturnal hemoglobinuria and in normal hematopoiesis. Leuk Lymphoma. 2006 Jul;47(7):1215-21. doi: 10.1080/10428190600555520.
- Gurnari C, Pagliuca S, Patel BJ, Awada H, Kongkiatkamon S, Terkawi L, Zawit M, Corey S, Lichtin AE, Carraway HE, Wahida A, Visconte V, Maciejewski JP. Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria. Leukemia. 2021 Aug;35(8):2431-2434. doi: 10.1038/s41375-020-01113-0. Epub 2021 Jan 22. No abstract available.
- Inoue N, Murakami Y, Kinoshita T. Molecular genetics of paroxysmal nocturnal hemoglobinuria. Int J Hematol. 2003 Feb;77(2):107-12. doi: 10.1007/BF02983208.
- Mortazavi Y, Merk B, McIntosh J, Marsh JC, Schrezenmeier H, Rutherford TR; BIOMED II Pathophysiology and Treatment of Aplastic Anaemia Study Group. The spectrum of PIG-A gene mutations in aplastic anemia/paroxysmal nocturnal hemoglobinuria (AA/PNH): a high incidence of multiple mutations and evidence of a mutational hot spot. Blood. 2003 Apr 1;101(7):2833-41. doi: 10.1182/blood-2002-07-2095. Epub 2002 Nov 7.
- Rosti V. The molecular basis of paroxysmal nocturnal hemoglobinuria. Haematologica. 2000 Jan;85(1):82-7.
- Tarailo-Graovac M, Sinclair G, Stockler-Ipsiroglu S, Van Allen M, Rozmus J, Shyr C, Biancheri R, Oh T, Sayson B, Lafek M, Ross CJ, Robinson WP, Wasserman WW, Rossi A, van Karnebeek CD. The genotypic and phenotypic spectrum of PIGA deficiency. Orphanet J Rare Dis. 2015 Feb 27;10:23. doi: 10.1186/s13023-015-0243-8.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
24 Feb 2022 | Neueste Version
1. Feb 2022 | Ursprünglich veröffentlicht
Nehmen Sie an der Diskussion teil
Teilen Sie Ihre Gedanken oder Erfahrungen mit anderen in unserem Patientengemeinschaften.
Fragen, teilen, verbinden.
Durchsuchen Sie Diskussionen, stellen Sie Fragen und teilen Sie Erfahrungen zu Hunderten von Gesundheitsthemen.
Abonnieren Sie den Patienten-Newsletter
Ihre wöchentliche Dosis klarer, vertrauenswürdiger Gesundheitsberatung - geschrieben, um Ihnen zu helfen, sich informiert, selbstbewusst und in Kontrolle zu fühlen.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.